Informations générales (source: ClinicalTrials.gov)
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
Interventional
N/A
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
mai 2021
octobre 2027
29 juin 2024
Non-small cell lung cancer (NSCLC) is a major public health problem. New treatments as
immunotherapy can improve prognosis of patients with NCLC tumors. Nevertheless, no robust
biomarker is actually available.
The hypothesis of the trial is to realize a longitudinal molecular monitoring of NSCLC
patients treated by immunotherapy using a quantitative analysis of cell-free DNA.
The primary purposes is to study the predictive value of quantification of cell-free DNA
at the first reevaluation time, on the clinical benefit, in NSCLC patients treated by
immunotherapy (regardless of line, or associated treatments) The secondary purposes in
this population of patients is to study the earlier predictive value (before the second
treatment by immunotherapy ) of quantification of cell-free DNA, and its relationship
with refractory disease and pseudo-progressive disease.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU de Besancon - Service de pneumologie - Besançon - France | WESTEEL Virginie, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHRU de Strasbourg - Strasbourg - France | BEAU-FALLER Michele, MD | Contact (sur clinicalTrials) | |||
| CHU de Dijon - service de Pneumologie - Dijon - France | FOUCHER Pascal, MD | Contact (sur clinicalTrials) | |||
| CHU de Reims - service de Pneumologie - Reims - France | DEWOLF Maxime, MD | Contact (sur clinicalTrials) | |||
| CLCC Georges-François Leclerc - Dijon - France | KADERBHAI Courèche, MD | Contact (sur clinicalTrials) | |||
| GHR Mulhouse Sud-Alsace - Service de Pneumologie - Mulhouse - France | DEBIEUVRE Didier, MD | Contact (sur clinicalTrials) | |||
| Hopitaux Civils de Colmar - service de Pneumologie - Colmar - France | MOREAU Lionel, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie de Lorraine - Vandœuvre-lès-Nancy - France | CLEMENT-DUCHENE Christelle, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- age over 18
- informed of the objectives of the project and signed consent
- non small cell lung cancer, stage IIIA, IIIB or IV
- PS (WHO performance status) < or =2
- treatment based on immunotherapy (monotherapy or combination)
- at least one measurable target
- available results of PD-L1 expression
- age over 18
- informed of the objectives of the project and signed consent
- non small cell lung cancer, stage IIIA, IIIB or IV
- PS (WHO performance status) < or =2
- treatment based on immunotherapy (monotherapy or combination)
- at least one measurable target
- available results of PD-L1 expression
- concomitant other type of cancer
- another cancer in the last 5 years